← All trials
NCT07231523
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- Jun 1, 2027
- Completion date
- Dec 1, 2027
- First posted
- Nov 17, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fudan UniversityLead sponsor
- Soochow UniversityCollaborator
- Xuzhou Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Guangzhou UniversityCollaborator
- People's Liberation Army of ChinaCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Sichuan UniversityCollaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.